Black Rock Inc. Verastem, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.39 - $0.71 $7,261 - $13,220	18,620 Added 0.65%	2,881,287 $1.21 Million
Q4 2022 Feb 13, 2023	SELL	$0.33 - $10.44 $465,905 - $14.7 Million	-1,411,835 Reduced 33.03%	2,862,667 $1.15 Million
Q3 2022 Nov 14, 2022	SELL	$0.92 - $11.16 $57,805 - $701,205	-62,832 Reduced 1.45%	4,274,502 $3.63 Million
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $8.01 Million - $14.4 Million	-7,852,159 Reduced 64.42%	4,337,334 $5.03 Million
Q1 2022 May 12, 2022	SELL	$1.06 - $2.1 $147,080 - $291,385	-138,755 Reduced 1.13%	12,189,493 $17.2 Million
Q4 2021 Feb 10, 2022	SELL	$2.05 - $3.2 $3,845 - $6,003	-1,876 Reduced 0.02%	12,328,248 $25.3 Million
Q3 2021 Nov 09, 2021	BUY	$2.54 - $4.07 $392,579 - $629,055	154,559 Added 1.27%	12,330,124 $38 Million
Q2 2021 Aug 11, 2021	BUY	$2.57 - $4.85 $31.3 Million - $59.1 Million	12,175,565 New	12,175,565 $49.6 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $838M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.